Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
124 hedge funds and large institutions have $467M invested in Orexigen Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 39 reducing their positions, and 28 closing their positions.
49% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $7.62M
15% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 39
2% less capital invested
Capital invested by funds: $475M → $467M (-$7.96M)
5% less funds holding
Funds holding: 130 → 124 (-6)
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$21.6M |
| 2 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$18.5M |
| 3 |
Millennium Management
New York
|
+$12.3M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$8.23M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.3M |
| 2 |
MG
Meditor Group
Hamilton,
Bermuda
|
-$12.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.17M |
| 4 |
Jennison Associates
New York
|
-$5.13M |
| 5 |
PC
Passport Capital
San Francisco,
California
|
-$4.6M |
OREX Hedge Fund Activity: Q4 2013 in Review
124 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q4 2013, worth a combined $467M — down 1.7% from $475M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of OREX and 23 opened new positions — a net loss of 5 holders — while 39 trimmed existing stakes and 45 added.
The largest buyer was Capital Research Global Investors, adding an estimated $21.6M. The largest seller was Fidelity Investments, cutting an estimated $13.3M.
- 124 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q4 2013, down from 130 in Q3 2013.
- Funds reported $467M of Orexigen Therapeutics, Inc. stock for Q4 2013, down 1.7% quarter-over-quarter.
- 23 funds opened new Orexigen Therapeutics, Inc. positions in Q4 2013 and 28 closed out, a net change of -5 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q4 2013 was Capital Research Global Investors, an estimated $21.6M added.
- The largest Orexigen Therapeutics, Inc. seller in Q4 2013 was Fidelity Investments, an estimated $13.3M sold.
Based on aggregated 13F filings for Q4 2013.